{"entity":{"id":"chris-lord","kind":"person","name":"Christopher Lord","aka":[],"tldr":"Co-discovered the synthetic lethality between PARP inhibition and BRCA loss that underlies PARP inhibitor therapy.","summary":"Christopher Lord is Professor of Cancer Genomics and Deputy Director of the Breast Cancer Now Research Centre at The Institute of Cancer Research. His specialisms are synthetic lethality, PARP inhibitors, DNA repair and drug resistance, with a focus on PARP and BRCA1/BRCA2. With Alan Ashworth he showed that BRCA-deficient cells are exquisitely sensitive to PARP inhibition, reported in Nature as a strategy for targeting the DNA repair defect in BRCA mutant cells, the discovery that underlies PARP inhibitor therapy. He has since mapped resistance mechanisms and new synthetic-lethal targets, and his Science review covered PARP inhibitors and synthetic lethality in the clinic. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lord%20CJ%5BAuthor%5D%20PARP%20synthetic%20lethality"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["parp-inhibitor","synthetic-lethality-approaches"],"targets":["parp","brca"],"drugs":[],"companies":[],"institutions":["icr-london"],"pathways":[],"terms":["synthetic-lethality"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cancer Genomics; Deputy Director, Breast Cancer Now Research Centre, ICR","institutionId":"icr-london","specialisms":["Synthetic lethality","PARP inhibitors","DNA repair","Drug resistance"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lord%20CJ%5BAuthor%5D%20PARP%20synthetic%20lethality"}],"papers":[{"title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","journal":"Nature","year":2005,"doi":"10.1038/nature03445"},{"title":"PARP inhibitors: synthetic lethality in the clinic","journal":"Science","year":2017,"doi":"10.1126/science.aam7344"}]},"route":"/people/chris-lord/","neighbours":{"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"institution":[{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/"}],"term":[{"id":"synthetic-lethality","kind":"term","name":"Synthetic lethality","route":"/terms/synthetic-lethality/"}],"idea":[{"id":"idea-fund-national-drug-development-office","kind":"idea","name":"Scale up public drug development that takes academic assets to phase 1","route":"/ideas/idea-fund-national-drug-development-office/"}]}}